» Articles » PMID: 30195742

Evaluation of a Few Discrete Clinical Markers May Predict Categorization of Actively Symptomatic Non-acute Schizophrenia Patients As Treatment Resistant or Responders: A Study by ROC Curve Analysis and Multivariate Analyses

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2018 Sep 10
PMID 30195742
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Here, we used Receiver Operating Characteristic (ROC) curve analysis to determine whether clinical factors may aid predicting the categorization of schizophrenia patients as Treatment Resistant (TRS) or antipsychotic responsive schizophrenia (ARS). Patients with an established condition of TRS or ARS were assessed for: clinical presentation and course; neurological soft signs (NES); psychopathology by PANSS; cognitive performances; quality of life scale (QLS); functional capacity; social functioning (PSP and SLOF scales). In ROC curve analysis, significance indicated that the Area under curve (AUC) allowed distinguishing between TRS and ARS. Multivariate analyses were additionally used to provide independent predictive analysis. Multiple clinical variables showed significant AUCs. The largest significant AUCs were found for: NES total score; SLOF Area2; QLS subscale; antipsychotic doses. The highest sensitivity was found for NES total score, the highest specificity for previous hospitalizations. The highest Odds Ratio of being included within the TRS category were found for: NES total score (7.5); QLS total score (5.49); and previous hospitalizations (4.76). This same circumscribed group of variables was also found to be predictive of TRS when adopting stepwise logistic regression or discriminant analysis. We concluded that the evaluation of few clinical factors may provide reliable and accurate predictions on whether one schizophrenia patient may be categorized as a TRS.

Citing Articles

Neurological Soft Signs in Schizophrenia, a Picture of the Knowledge in the Last Decade: A Scoping Review.

Petrescu C, Petrescu D, Marian G, Focseneanu B, Iliuta F, Ciobanu C Healthcare (Basel). 2023; 11(10).

PMID: 37239757 PMC: 10217815. DOI: 10.3390/healthcare11101471.


Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance.

de Bartolomeis A, De Simone G, Ciccarelli M, Castiello A, Mazza B, Vellucci L Biomedicines. 2022; 10(12).

PMID: 36551939 PMC: 9776416. DOI: 10.3390/biomedicines10123183.


Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis.

Millgate E, Hide O, Lawrie S, Murray R, MacCabe J, Kravariti E Psychol Med. 2022; 52(1):1-13.

PMID: 36415088 PMC: 8711103. DOI: 10.1017/S0033291721004128.


Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium.

Smart S, Agbedjro D, Pardinas A, Ajnakina O, Alameda L, Andreassen O Schizophr Res. 2022; 250:1-9.

PMID: 36242784 PMC: 9834064. DOI: 10.1016/j.schres.2022.09.009.


A predictor model of treatment resistance in schizophrenia using data from electronic health records.

Kadra-Scalzo G, Fonseca de Freitas D, Agbedjro D, Francis E, Ridler I, Pritchard M PLoS One. 2022; 17(9):e0274864.

PMID: 36121864 PMC: 9484642. DOI: 10.1371/journal.pone.0274864.